Skip to main content

Drug Interactions between levamisole and talimogene laherparepvec

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

levamisole talimogene laherparepvec

Applies to: levamisole and talimogene laherparepvec

CONTRAINDICATED: Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.

MANAGEMENT: Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.

References

  1. (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA

Switch to consumer interaction data

Drug and food interactions

Moderate

levamisole food

Applies to: levamisole

GENERALLY AVOID: Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol. These side effects could be alleviated by total abstinence from alcohol. No mechanism has been established for this interaction.

MANAGEMENT: Patients receiving levamisole should avoid alcohol.

References

  1. (2001) "Product Information. Ergamisol (levamisole)." Janssen Pharmaceuticals
  2. Renoux G (1980) "The general immunopharmacology of levamisole." Drugs, 19, p. 89-99
  3. Renoux G (1978) "Modulation of immunity by levamisole." Pharmacol Ther [B], 2, p. 397-422

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer